Stock Price

0,16 CAD

0% ROA

-125.32% ROE

0x PER

Market Cap.

0,00 CAD

0% DER

0% Yield

-14550.71% NPM

LexaGene Holdings Inc. Stock Analysis

LexaGene Holdings Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

LexaGene Holdings Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

LexaGene Holdings Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

LexaGene Holdings Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Unknown
2 MACD Unknown
3 RSI Unknown
4 Stoch RSI Unknown

LexaGene Holdings Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

LexaGene Holdings Inc. Revenue
Year Revenue Growth
2014 0
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 73.983 100%
2021 95.476 22.51%
2022 230.894 58.65%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

LexaGene Holdings Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2014 0
2015 0 0%
2016 593.202 100%
2017 3.190.006 81.4%
2018 7.085.193 54.98%
2019 5.983.861 -18.41%
2020 7.544.413 20.68%
2021 7.631.789 1.14%
2022 4.774.432 -59.85%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

LexaGene Holdings Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 78.972
2015 75.762 -4.24%
2016 252.833 70.04%
2017 769.120 67.13%
2018 2.205.004 65.12%
2019 2.869.284 23.15%
2020 2.989.729 4.03%
2021 2.864.497 -4.37%
2022 2.442.848 -17.26%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

LexaGene Holdings Inc. EBITDA
Year EBITDA Growth
2014 0
2015 -75.762 100%
2016 -1.282.919 94.09%
2017 -5.079.437 74.74%
2018 -10.772.143 52.85%
2019 -9.863.666 -9.21%
2020 -12.822.750 23.08%
2021 -13.670.108 6.2%
2022 -8.707.180 -57%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

LexaGene Holdings Inc. Gross Profit
Year Gross Profit Growth
2014 0
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 -129.631 100%
2021 -593.330 78.15%
2022 -791.038 24.99%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

LexaGene Holdings Inc. Net Profit
Year Net Profit Growth
2014 -78.972
2015 -80.378 1.75%
2016 -5.954.202 98.65%
2017 -5.139.675 -15.85%
2018 -10.950.262 53.06%
2019 -10.067.776 -8.77%
2020 -13.038.018 22.78%
2021 -13.892.440 6.15%
2022 -9.030.624 -53.84%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

LexaGene Holdings Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 0
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

LexaGene Holdings Inc. Free Cashflow
Year Free Cashflow Growth
2014 0
2015 -51.533 100%
2016 -1.431.622 96.4%
2017 -5.550.983 74.21%
2018 -8.059.926 31.13%
2019 -7.353.461 -9.61%
2020 -11.611.962 36.67%
2021 -12.266.267 5.33%
2022 -2.191.993 -459.59%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

LexaGene Holdings Inc. Operating Cashflow
Year Operating Cashflow Growth
2014 0
2015 -51.533 100%
2016 -1.387.530 96.29%
2017 -4.700.605 70.48%
2018 -7.893.839 40.45%
2019 -7.267.671 -8.62%
2020 -11.525.250 36.94%
2021 -12.243.626 5.87%
2022 -2.191.993 -458.56%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

LexaGene Holdings Inc. Capital Expenditure
Year Capital Expenditure Growth
2014 0
2015 0 0%
2016 44.092 100%
2017 850.378 94.82%
2018 166.087 -412.01%
2019 85.790 -93.6%
2020 86.712 1.06%
2021 22.641 -282.99%
2022 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

LexaGene Holdings Inc. Equity
Year Equity Growth
2014 -5.591
2015 39.888 114.02%
2016 1.224.064 96.74%
2017 4.448.330 72.48%
2018 1.822.146 -144.13%
2019 5.175.754 64.79%
2020 13.974.886 62.96%
2021 8.197.049 -70.49%
2022 1.712.672 -378.61%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

LexaGene Holdings Inc. Assets
Year Assets Growth
2014 7.335
2015 104.571 92.99%
2016 1.397.535 92.52%
2017 4.778.739 70.76%
2018 2.242.177 -113.13%
2019 8.040.111 72.11%
2020 16.774.756 52.07%
2021 10.396.264 -61.35%
2022 4.694.290 -121.47%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

LexaGene Holdings Inc. Liabilities
Year Liabilities Growth
2014 12.926
2015 64.683 80.02%
2016 173.471 62.71%
2017 330.408 47.5%
2018 420.031 21.34%
2019 2.864.357 85.34%
2020 1.347.222 -112.61%
2021 2.199.214 38.74%
2022 2.981.618 26.24%

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

LexaGene Holdings Inc. Dividends
Year Dividends Growth

LexaGene Holdings Inc. Profile

About LexaGene Holdings Inc.

LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts.

CEO
Dr. John F. Regan
Employee
33
Address
500 Cummings Center
Beverly, 01915

LexaGene Holdings Inc. Executives & BODs

LexaGene Holdings Inc. Executives & BODs
# Name Age
1 Dr. John F. Regan
Founder, Chairman & Chief Executive Officer
70
2 Mr. Jeffrey Mitchell
Chief Financial Officer, Treasurer & Corporation Sec.
70
3 Mr. Steven Armstrong
Chief Operating Officer
70
4 Mr. Allan John Fabbro
Vice President of Corporation Devel.
70
5 Nicole Ridgedale
Director of Corporation Marketing
70
6 Mr. Jay Adelaar
Vice President of Capital Markets
70

LexaGene Holdings Inc. Competitors